Alcon Laboratories Inc. positions its third olopatadine eye drop formulation approved for an Rx-to-OTC switch in the US in 2020 as an ocular allergy remedy for consumers who need 24-hour doses.
The US division of Swiss firm Alcon Inc. on 13 July announced Pataday Once Daily Relief Extra Strength (olopatadine...







